Галерея 2929287

Галерея 2929287

Alle Titel TV-Folgen Prominente Unternehmen Stichwörter Erweiterte Suche
Vollständig unterstützt English (United States) Teilweise unterstützt Diese Seite ist in der von dir ausgewählten Sprache nicht verfügbar. Français (Canada) Français (France) Deutsch (Deutschland) हिंदी (भारत) Italiano (Italia) Português (Brasil) Español (España) Español (México)

Filmography

by Year

by Job

by Ratings

by Votes

by Genre

by Keyword

Did You Know?

Personal Quotes

Trivia

Trademark

Photo & Video

Photo Gallery

Trailers and Videos

Opinion

Awards

Related Items

Credited With

News

External Sites

Professional Services

Get more at IMDbPro

Melde dich an für Zugriff auf mehr Inhalte Melde dich an für Zugriff auf mehr Inhalte

Evi Athanasoula is known for Tis agapis mahairia (2006).

Other Works

|
Publicity Listings

|
Official Sites

Dashboard
Publications
Account settings
Log out

Journal List

HHS Author Manuscripts

PMC2929287

Create a new collection

Add to an existing collection

Unable to load your collection due to an error
Please try again

Nat Rev Clin Oncol. Author manuscript; available in PMC 2010 Nov 1.
Deric L. Wheeler, Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, 1111 Highland Avenue Madison, WI 53705, USA;
Correspondence to: D. L. Wheeler ude.csiw@releehwld
The publisher's final edited version of this article is available at Nat Rev Clin Oncol
1. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J. Biol. Chem. 1962; 237 :1555–1562. [ PubMed ] [ Google Scholar ]
2. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF) Dev. Biol. 1965; 12 :394–407. [ PubMed ] [ Google Scholar ]
3. Carpenter G, Lembach KJ, Morrison MM, Cohen S. Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. J. Biol. Chem. 1975; 250 :4297–4304. [ PubMed ] [ Google Scholar ]
4. Carpenter G, King L, Jr, Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro . Nature. 1978; 276 :409–410. [ PubMed ] [ Google Scholar ]
5. Ullrich A, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984; 309 :418–425. [ PubMed ] [ Google Scholar ]
6. Eckhart W, Hutchinson MA, Hunter T. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates. Cell. 1979; 18 :925–933. [ PubMed ] [ Google Scholar ]
7. Hunter T, Sefton BM. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl Acad. Sci. USA. 1980; 77 :1311–1315. [ PMC free article ] [ PubMed ] [ Google Scholar ]
8. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001; 2 :127–137. [ PubMed ] [ Google Scholar ]
9. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 2004; 58 :903–913. [ PubMed ] [ Google Scholar ]
10. Libermann TA, et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984; 44 :753–760. [ PubMed ] [ Google Scholar ]
11. Libermann TA, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985; 313 :144–147. [ PubMed ] [ Google Scholar ]
12. Libermann TA, et al. Amplification and overexpression of the EGF receptor gene in primary human glioblastomas. J. Cell Sci. Suppl. 1985; 3 :161–172. [ PubMed ] [ Google Scholar ]
13. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer. 1987; 55 :513–516. [ PMC free article ] [ PubMed ] [ Google Scholar ]
14. Weichselbaum RR, et al. Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck. 1989; 11 :437–442. [ PubMed ] [ Google Scholar ]
15. Sato JD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1983; 1 :511–529. [ PubMed ] [ Google Scholar ]
16. Kawamoto T, et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl Acad. Sci. USA. 1983; 80 :1337–1341. [ PMC free article ] [ PubMed ] [ Google Scholar ]
17. Honegger AM, et al. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell. 1987; 51 :199–209. [ PubMed ] [ Google Scholar ]
18. Honegger AM, et al. A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis. Mol. Cell. Biol. 1987; 7 :4568–4571. [ PMC free article ] [ PubMed ] [ Google Scholar ]
19. Redemann N, et al. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol. Cell. Biol. 1992; 12 :491–498. [ PMC free article ] [ PubMed ] [ Google Scholar ]
20. Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994; 265 :1093–1095. [ PubMed ] [ Google Scholar ]
21. Osherov N, Levitzki A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur. J. Biochem. 1994; 225 :1047–1053. [ PubMed ] [ Google Scholar ]
22. Wakeling AE, et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 1996; 38 :67–73. [ PubMed ] [ Google Scholar ]
23. Bonner JA, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006; 354 :567–578. [ PubMed ] [ Google Scholar ]
24. Herbst RS, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J. Clin. Oncol. 2004; 22 :785–794. [ PubMed ] [ Google Scholar ]
25. Thatcher N, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet. 2005; 366 :1527–1537. [ PubMed ] [ Google Scholar ]
26. Borner M, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann. Oncol. 2008; 19 :1288–1292. [ PubMed ] [ Google Scholar ]
27. Sobrero AF, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008; 26 :2311–2319. [ PubMed ] [ Google Scholar ]
28. Moore MJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007; 25 :1960–1966. [ PubMed ] [ Google Scholar ]
29. Senderowicz AM, et al. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) 2007; 21 :1696–1706. [ PubMed ] [ Google Scholar ]
30. Di Leo A, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 2008; 26 :5544–5552. [ PMC free article ] [ PubMed ] [ Google Scholar ]
31. Jackman D, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 2010; 28 :357–360. [ PMC free article ] [ PubMed ] [ Google Scholar ]
32. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer. 2005; 5 :341–354. [ PubMed ] [ Google Scholar ]
33. Klapper LN, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl Acad. Sci. USA. 1999; 96 :4995–5000. [ PMC free article ] [ PubMed ] [ Google Scholar ]
34. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer. 2009; 9 :463–475. [ PubMed ] [ Google Scholar ]
35. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL., 3rd Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl Acad. Sci. USA. 1994; 91 :8132–8136. [ PMC free article ] [ PubMed ] [ Google Scholar ]
36. Wallasch C, et al. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995; 14 :4267–4275. [ PMC free article ] [ PubMed ] [ Google Scholar ]
37. Weihua Z, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 2008; 13 :385–393. [ PMC free article ] [ PubMed ] [ Google Scholar ]
38. Marti U, et al. Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology. 1991; 13 :15–20. [ PubMed ] [ Google Scholar ]
39. Cao H, Lei ZM, Bian L, Rao CV. Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. Endocrinology. 1995; 136 :3163–3172. [ PubMed ] [ Google Scholar ]
40. Lin SY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001; 3 :802–808. [ PubMed ] [ Google Scholar ]
41. Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res. Treat. 2006; 95 :211–218. [ PubMed ] [ Google Scholar ]
42. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br. J. Cancer. 2006; 94 :184–188. [ PMC free article ] [ PubMed ] [ Google Scholar ]
43. Lo HW, et al. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005; 65 :338–348. [ PubMed ] [ Google Scholar ]
44. Psyrri A, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin. Cancer Res. 2005; 11 :5856–5862. [ PubMed ] [ Google Scholar ]
45. Xia W, et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol. Carcinog. 2009; 48 :610–617. [ PMC free article ] [ PubMed ] [ Google Scholar ]
46. Hanada N, et al. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol. Carcinog. 2006; 45 :10–17. [ PubMed ] [ Google Scholar ]
47. Lo HW, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 2005; 7 :575–589. [ PubMed ] [ Google Scholar ]
48. Lo HW, Cao X, Zhu H, Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol. Cancer Res. 2010; 8 :232–245. [ PMC free article ] [ PubMed ] [ Google Scholar ]
49. Hsu SC, Hung MC. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J. Biol. Chem. 2007; 282 :10432–10440. [ PubMed ] [ Google Scholar ]
50. Lo HW, et al. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J. Cell. Biochem. 2006; 98 :1570–1583. [ PubMed ] [ Google Scholar ]
51. Liao HJ, Carpenter G. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol. Biol. Cell. 2007; 18 :1064–1072. [ PMC free article ] [ PubMed ] [ Google Scholar ]
52. Hung LY, et al. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res. 2008; 36 :4337–4351. [ PMC free article ] [ PubMed ] [ Google Scholar ]
53. Wang SC, et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat. Cell Biol. 2006; 8 :1359–1368. [ PubMed ] [ Google Scholar ]
54. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995; 1 :1311–1318. [ PubMed ] [ Google Scholar ]
55. Kimura H, et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007; 98 :1275–1280. [ PubMed ] [ Google Scholar ]
56. Van Cutsem E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009; 360 :1408–1417. [ PubMed ] [ Google Scholar ]
57. Saltz LB, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 2007; 25 :4557–4561. [ PubMed ] [ Google Scholar ]
58. Jonker DJ, et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007; 357 :2040–2048. [ PubMed ] [ Google Scholar ]
59. Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004; 351 :337–345. [ PubMed ] [ Google Scholar ]
60. Vermorken JB, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008; 359 :1116–1127. [ PubMed ] [ Google Scholar ]
61. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2005; 23 :8646–8654. [ PubMed ] [ Google Scholar ]
62. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 2001; 38 :17–23. [ PubMed ] [ Google Scholar ]
63. Yang XD, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999; 59 :1236–1243. [ PubMed ] [ Google Scholar ]
64. Hecht JR, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 2009; 27 :672–680. [ PubMed ] [ Google Scholar ]
65. Giusti RM, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin. Cancer Res. 2008; 14 :1296–1302. [ PubMed ] [ Google Scholar ]
66. Van Cutsem E, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007; 25 :1658–1664. [ PubMed ] [ Google Scholar ]
67. Kris MG, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290 :2149–2158. [ PubMed ] [ Google Scholar ]
68. Fukuoka M, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) J. Clin. Oncol. 2003; 21 :2237–2246. [ PubMed ] [ Google Scholar ]
69. Giaccone G, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J. Clin. Oncol. 2004; 22 :777–784. [ PubMed ] [ Google Scholar ]
70. Herbst RS, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005; 23 :5892–5899. [ PubMed ] [ Google Scholar ]
71. Gatzemeier U, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 2007; 25 :1545–1552. [ PubMed ] [ Google Scholar ]
72. Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353 :123–132. [ PubMed ] [ Google Scholar ]
73. Tsao MS, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N. Engl. J. Med. 2005; 353 :133–144. [ PubMed ] [ Google Scholar ]
74. Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304 :1497–1500. [ PubMed ] [ Google Scholar ]
75. Lynch TJ, et al. Activating mutations in the epidermal growth factor r
Опытные лесби Чарли и Криста
Некая арабка покушала спермы
Фут фетиш пожилых лесбиянок

Галерея 2929287

Report Page